普林斯顿，新泽西州，美国— Envigo announced today it will launch the “R2G2” mouse at the American Association for Cancer Research (AACR) annual meeting in Washington DC, April 1-5, 2017. The R2G2, a Rag2/IL2RG double knockout model, was created by backcrossing the common gamma chain gene mutation (IL2RG) on to a unique C57BL/6 and 129 mixed background mouse with a mutation in the recombination activating gene 2 (Rag2). The R2G2 mouse addresses common challenges that researchers experience with current models used in oncology, immuno-oncology and infectious disease research.

R2G2与其他具有scid突变的三重免疫缺陷模型相比具有明显的优势。使其成为肿瘤学研究理想的一个关键优点是模型的放射敏感性降低，这意味着它有能力耐受更大范围的辐射剂量的影响。这有助于研究人员更密切地模拟癌症治疗的治疗环境，在那里病人接受化疗/免疫治疗和放疗的组合。由于Rag2和IL2rg基因的破坏导致缺乏功能性T、B和NK细胞，该模型具有高度免疫缺陷。此外，与其他几种scid突变的模型相比，R2G2还带来了减少“漏泄”的好处——scid突变的免疫系统会随着年龄的增长而再生，形成新的T细胞，这会混淆实验。

合同研究Ser总裁迈克·考尔菲德vices and Research Model Services in North America at Envigo, commented: “R2G2 is a genetically engineered model (GEM) and its launch forms part of Envigo’s wider commitment to expand the number of GEMs in our portfolio, and provide researchers with new models that address limitations they encounter with other mice currently used for research in oncology and infectious disease. Already, radiosensitivity testing has proven this model is less sensitive and flow cytometry has demonstrated that the immune profile is similar to the NSG™ model. In short, R2G2 provides a translational research approach that will help customers to more accurately predict outcomes.”

除了已经完成的实验外，Envigo目前正在验证该模型潜在的人性化优势，其结果将在初夏公布。EnvigB0B体育平台下载o在R2G2上汇编的数据在一份白皮书中概述，该白皮书将在AACR和Envigo的网站上分发。Envigo将继续收集有关该模型的数据，并希望与愿意根据R2G2小鼠在研究中的应用提供见解的研究人员合作。